Clinical Benefit of Avapritinib in <i>KIT-</i> Mutant Gastrointestinal Stromal Tumors: A <i>Post Hoc</i> Analysis of the Phase I NAVIGATOR and Phase I/II CS3007–001 Studies

Michael C. Heinrich(VA Portland Health Care System), Lin Shen(Peking University), Shirong Cai(Sun Yat-sen University), Meining Wang(Suzhou Research Institute), Sebastian Bauer(Science for Life Laboratory), Yuehong Cui, Kaixiong Tao(Wuhan Union Hospital), Robin L. Jones(Institute of Cancer Research), César Serrano(Vall d'Hebron Institut de Recerca), Zhichao Zheng(Stomatology Hospital), Jin Hu(Suzhou Research Institute), Suzanne George(Dana-Farber Cancer Institute), Jian Li(Beijing Normal University), Yongjian Zhou(Fujian Medical University), Jason Yang(Suzhou Research Institute), Hui Cao(Shanghai Jiao Tong University), Xinhua Zhang(Sun Yat-sen University), Yanhong Deng(Sun Yat-sen University), Jun Zhang(The Affiliated Yongchuan Hospital of Chongqing Medical University), Xin Wu(Chinese PLA General Hospital)
Clinical Cancer Research
November 30, 2023
10.1158/1078-0432.ccr-23-1861
Cited by 9

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
|The Lancet|2012|1.4k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k
Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
|Annals of Oncology|2021|978